Skip to main content
OpenTrials
Completed

NCT Number: NCT06633289

Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy

The purpose of the study is to determine whether a new hydrolyzed rice protein-based formula is hypoallergenic in infants and young children with documented Immunoglobulin E (IgE)-mediated Cow Milk Protein Allergy (CMPA).

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 day–3 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Charité - Universitätsmedizin Berlin Klinik für Pädiatrie m.S. Pneumologie/Immunologie, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent has been obtained from at least one parent (or legally acceptable representative [LAR]), if applicable)
  • Child gestational age ≥ 37 completed weeks
  • Child aged ≥ 60 days and less than 36 months at enrollment
  • Documented IgE-mediated CMPA no more than 6 months prior to enrollment
  • Child is receiving a strict cow's milk elimination diet and will continue receiving this diet until the completion of the study
  • Child's parent(s) and LAR (if applicable) is of legal age of majority, must have parental authority, must understand the informed consent form and other study documents, and are willing and able to fulfill the requirements of the study protocol

Exclusion criteria

  • Child is exclusively breastfed
  • Any chronic medical diseases (except atopic eczema), chromosomal or major congenital anomalies
  • Congenital heart disease or treatment by B-blockers
  • Major gastrointestinal disease / abnormalities (other than CMPA)
  • Known or suspected soy allergy
  • Glucose-galactose malabsorption
  • Immunodeficiency
  • Children who are unable to discontinue antihistamine use (excluding eye drops) within 7 days prior to a food challenge and oral steroid use within 14 days prior to enrollment
  • Persistent wheeze or chronic respiratory disease
  • Severe uncontrolled eczema or urticaria
  • Rice protein allergy or intolerance (e.g., rice protein-induced enterocolitis syndrome), or allergy to any ingredient in the formulas
  • Child's parent has other medical or psychiatric condition that, in the judgement of the Investigator, would make the child inappropriate for entry into the study
  • Currently participating or having participated in another interventional clinical study within 4 weeks prior to enrollment
  • Child's parents have not reached legal age of majority (18 years).

Treatment and study plan

Experimental formula

Other

New hydrolyzed rice protein-based formula

Control Formula

Other

Commercially available amino acid-based formula.

Primary outcomes

  1. Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula (Experimental Formula)

    Time frame: during test day

    by measuring the proportion of participants who "passed" the food challenge test, meaning who consumed all doses and exhibited no allergic reactions to any of the doses of the experimental formula.

Secondary outcomes

  1. Gastrointestinal tolerance of experimental formula during at home consumption period

    Time frame: during 7 days

    by evaluating gastrointestinal symptoms, using information recorded by parents daily in a diary

  2. Safety of experimental formula during the at-home consumption

    Time frame: during 7 days

    By assessing the frequency and severity of adverse events reported by parents during the home usage phase

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy: a Randomized Nutritional Clinical Study

Acronym: RIGHT-HY

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 9, 2024
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.